Half-Life of Platelet Factor 4 (PF-4) in Plasma and Platelets from Macaca Mulatta

Knut Gjesdal; Duncan S. Pepper

doi:10.1055/s-0038-1649203

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 1977; 37(01): 073-080
DOI: 10.1055/s-0038-1649203

Original Article

Schattauer GmbH

Half-Life of Platelet Factor 4 (PF-4) in Plasma and Platelets from Macaca Mulatta

Authors

Knut Gjesdal

¹Department of Internal Medicine, Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway

²Edinburgh and South-East Scotland Regional Blood Transfusion Service, Royal Infirmary, Edinburgh, Scotland
Duncan S. Pepper

¹Department of Internal Medicine, Institute of Clinical Medicine, University of Tromsø, Tromsø, Norway

²Edinburgh and South-East Scotland Regional Blood Transfusion Service, Royal Infirmary, Edinburgh, Scotland

Abstract

PDF Download

Summary

Human platelet factor 4 (PF-4) showed a reaction of complete identity with PF-4 from Macaca mulatta when tested against rabbit anti-human-PF-4. Such immunoglobulin was used for quantitative precipitation of in vivo labelled PF-4 in monkey serum. The results suggest that the active protein had an intra-platelet half-life of about 21 hours. In vitro ¹²⁵I-labelled human PF-4 was injected intravenously into two monkeys and isolated by immuno-precipita-tion from platelet-poor plasma and from platelets disrupted after gel-filtration. Plasma PF-4 was found to have a half-life of 7 to 11 hours. Some of the labelled PF-4 was associated with platelets and this fraction had a rapid initial disappearance rate and a subsequent half-life close to that of plasma PF-4. The results are compatible with the hypothesis that granular PF-4 belongs to a separate compartment, whereas membrane-bound PF-4 and plasma PF-4 may interchange.

PDF (9948 kb)

References

References
1 Barber A.J, Käser-Glanzmann R, Jakabova M, Lüscher E.F. Characterization of a chondroitin 4-sulphate proteoglycan carrier for heparin neutralizing activity (platelet factor 4) released from human blood platelets. Biochimica et Biophysica Acta 1972; 286: 312
2 Bull B.S, Schneiderman M.A, Brecher G. Platelet counts with the Coulter Counter. American Journal of Clinical Pathology 1965; 44: 678
3 Day H.J, Stormorken A, Holmsen H. Subcellular localization of platelet factor 3 and platelet factor 4. Scandinavian Journal of Haematology 1973; 10: 254
4 Fuster V, Bowie E.J.W, Kazmier F.J, Owen C.A. Platelet consumption in chronically induced plasma platelet factor 4-like activity reflecting rate of intravascular coagulation in dogs. Thrombosis Research 1974; 4: 247
5 Gaudernack G, Berre Å.G, Østerud B, Prydz H. Immunological studies on the blood coagulation factor X and its warfarin-induced precursor. Thrombosis et Diathesis haemorrhagica 1974; 31: 40
6 Gaudernack G, Prydz H. Studies of PIVKA-X. Thrombosis et Diathesis haemorrhagica 1975; 34: 455
7 Gjesdal K. Platelet factor (PF-4). An electroimmuno assay for PF-4 in human plasma. Scandinavian Journal of Haematology 1974; 13: 232
8 Gjesdal K, Nordøy A, Wang H, Berntsen H, Mjøs O.D. Effects of fasting on plasma and platelet free fatty acids and platelet function in healthy males. Thrombosis and Haemostasis 1976; 36: 325
9 Greenwood F.C, Hunter W.M, Glover J.S. The preparation of ¹³¹I-labelled human growth hormone of high specific radioactivity. Biochemical Journal 1963; 89: 114
10 Moore S, Pepper D.S, Cash J.D. Platelet antiheparin activity. The isolation and characterization of platelet factor 4 released from thrombin-aggregated washed human platelets and its dissociation into subunits and the isolation of membrane-bound antiheparin activity. Biochemica et Biophysica Acta 1975; 379: 370
11 Niewjarowski S, Lipinski B, Farbiszewski R, Poplawski A. The release of platelet factor 4 during platelet aggregation and the possible significance of this reaction in hemostasis. Experien-tia 1968; 24: 343
12 Nmwiarowski S, Lowery C.T, Hawiger J, Millman M, Timmons S. Immunoassay of human platelet factor 4 (PF-4, antiheparin factor) by radial immunodiffusion. Journal of Laboratory and Clinical Medicine 1976; 87: 720
13 O’Brien J.R, Finch W, Clark E. Platelet-bound and soluble platelet factor 4: Effects of aggregating agents, of aggregation, and of aspirin. Proceedings of the Society for experimental Biology and Medicine 1970; 234: 1128
14 Schulze H.E, Heremans J.F. Molecular Biology of human Proteins with special Reference to Plasma Proteins . 1966. Elsevier publishing company; Amsterdam, London, New York:
15 Sear C.H.J, Poller L. Antiheparin activity of human serum and platelet factor 4. Thrombosis et Diathesis haemorrhagica 1973; 30: 93
16 Stormorken H. The platelet release reaction. Its general aspects and relation to phagocytosis/pinocytosis. Scandinavian Journal of clinical and Laboratory Investigation Suppl. 1969; 107: 115
17 Tangen O, Berman H.J. Gelfiltration of blood platelets: a methodological report. In: Mannucci P.M, Gorini S. (ed.) Platelet Function and Thrombosis. Advances in experimental Medicine and Biology. vol. 34 1973. New York.; Plenum publishing Corp.: p. 235
18 Youssef A, Barkhan P. Release of platelet factor 4 by adenosine diphosphate and other platelet aggregating agents. British Medical Journal 1968; 1: 746